Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210896 | 0.85 | CYP3A4 (0.60) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL28554406 | 0.82 | TDP1 (0.44) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL2768908 | 0.80 | ALDH1A1 (0.46) | CYP3A4TDP1GABRA1GABRB2HTR3E | |
| SCHEMBL93182 | 0.79 | CYP3A4 (0.54) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL29862583 | 0.79 | CYP3A4 (0.54) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL29662014 | 0.79 | CYP3A4 (0.54) | CYP3A4TDP1GABRA1GABRB2TRPA1 | |
| SCHEMBL1595410 | 0.79 | CYP3A4 (0.54) | CYP3A4TDP1GABRA1GABRB2TRPA1 | |
| SCHEMBL29537333 | 0.79 | CYP3A4 (0.52) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL93270 | 0.79 | CYP3A4 (0.52) | CYP3A4TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL462306 | 0.78 | CYP3A4 (0.52) | CYP3A4TDP1GABRA1GABRB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118525003-A | Novel heteroaryl urea compounds as KV7.2 inhibitors | 伊卡根有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| CN-101617036-A | Benefit agent delivery compositions | PROCTER & GAMBLE | 2009-12-30 | — | — | CN | disclosed |
| EP-2111443-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | The Procter and Gamble Company (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200363-A1 | Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost | PROECTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | disclosed |
| WO-2008100601-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2008-08-21 | — | — | WO | disclosed |
| CN-1090623-C | 3-aryl-1, 2, 4-triazole derivatives having herbicidal properties | BAYER AG (DE) | 2002-09-11 | — | — | CN | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| CN-1325848-A | Herbicidal 3-aryl-1,2,4-triazole derivative | BAYER AG (DE) | 2001-12-12 | — | — | CN | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| CN-1175249-A | 3-aryl-1, 2, 4-triazole derivatives having herbicidal properties | BAYER AG (DE) | 1998-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | CYP3A4 18/4885TDP1 2961/4885GABRA1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.